Rosuvastatin calcium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319524

CAS#: 147098-20-2 (calcium)

Description: Rosuvastatin, also known as S-4522 and ZD 4522, is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to treat high cholesterol and related conditions, and to prevent cardiovascular disease. Rosuvastatin is a competitive inhibitor of the enzyme HMG-CoA reductase, having a mechanism of action similar to that of other statins. Its approximate elimination half life is 19 h and its time to peak plasma concentration is reached in 3–5 h following oral administration. Putative beneficial effects of rosuvastatin therapy on chronic heart failure may be negated by increases in collagen turnover markers as well as a reduction in plasma coenzyme Q10 levels in patients with chronic heart failure.

Chemical Structure

Rosuvastatin calcium
CAS# 147098-20-2 (calcium)

Theoretical Analysis

MedKoo Cat#: 319524
Name: Rosuvastatin calcium
CAS#: 147098-20-2 (calcium)
Chemical Formula: C44H54CaF2N6O12S
Exact Mass:
Molecular Weight: 1001.14
Elemental Analysis: C, 52.79; H, 5.44; Ca, 4.00; F, 3.80; N, 8.39; O, 19.18; S, 6.40

Price and Availability

Size Price Availability Quantity
1.0g USD 150.0 Same day
2.0g USD 250.0 Same day
5.0g USD 450.0 Same day
10.0g USD 750.0 Same day
20.0g USD 1250.0 Same day
50.0g USD 1950.0 Same day
100.0g USD 2950.0 Same day
200.0g USD 3950.0 Same day
1.0kg USD 8250.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Related CAS #: 147098-20-2 (calcium)   287714-41-4 (free acid)    

Synonym: S-4522; S 4522; S4522; ZD 4522; ZD-4522; ZD4522; ZD 4522 calcium salt; Rosuvastatin calcium, trade name: Crestor.

IUPAC/Chemical Name: calcium (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate


InChi Code: InChI=1S/2C22H28FN3O6S.Ca/c2*1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32;/h2*5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30);/q;;+2/p-2/b2*10-9+;

SMILES Code: CC(C1=NC(=NC(=C1/C=C/C(O)CC(O)CC(=O)[O-])C2=CC=C(C=C2)F)N(S(=O)(=O)C)C)C.CC(C1=NC(=NC(=C1/C=C/C(O)CC(O)CC(=O)[O-])C2=CC=C(C=C2)F)N(S(=O)(=O)C)C)C.[Ca+2]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO and water.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1001.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Yang Y, Wu YX, Hu YZ. Rosuvastatin Treatment for Preventing Contrast-Induced Acute Kidney Injury After Cardiac Catheterization: A Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore). 2015 Jul;94(30):e1226. doi: 10.1097/MD.0000000000001226. Review. PubMed PMID: 26222855; PubMed Central PMCID: PMC4554112.

2: Drapkina OM, Eliashevich SO. [Efficacy and Safety of Rosuvastatin in Patients of Different Risk Groups of Developing Cardiovascular Diseases]. Kardiologiia. 2015;55(2):72-81. Review. Russian. PubMed PMID: 26164992.

3: Laufs U. [Lipid lowering by rosuvastatin: how do statins differ?]. Dtsch Med Wochenschr. 2015 Mar;140(5):313. doi: 10.1055/s-0041-100713. Epub 2015 Mar 3. Review. German. PubMed PMID: 25734669.

4: Adams SP, Sekhon SS, Wright JM. Lipid-lowering efficacy of rosuvastatin. Cochrane Database Syst Rev. 2014 Nov 21;11:CD010254. doi: 10.1002/14651858.CD010254.pub2. Review. PubMed PMID: 25415541.

5: Kostapanos MS, Rizos CV, Elisaf MS. Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases. Drug Saf. 2014 Jul;37(7):481-500. doi: 10.1007/s40264-014-0169-4. Review. PubMed PMID: 24788803.

6: Toth PP. An update on the benefits and risks of rosuvastatin therapy. Postgrad Med. 2014 Mar;126(2):7-17. doi: 10.3810/pgm.2014.03.2736. Review. PubMed PMID: 24685964.

7: Wang Z, Ge J. Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin. Clin Interv Aging. 2014;9:1-8. doi: 10.2147/CIA.S41356. Epub 2013 Dec 9. Review. PubMed PMID: 24353409; PubMed Central PMCID: PMC3861292.

8: Takagi H, Umemoto T; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A meta-analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles. Am J Cardiol. 2014 Jan 15;113(2):292-301. doi: 10.1016/j.amjcard.2013.08.043. Epub 2013 Oct 3. Review. PubMed PMID: 24230979.

9: Hu M, Tomlinson B. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):51-65. doi: 10.1517/17425255.2014.851667. Epub 2013 Oct 25. Review. PubMed PMID: 24156555.

10: Mahalwar R, Khanna D. Pleiotropic antioxidant potential of rosuvastatin in preventing cardiovascular disorders. Eur J Pharmacol. 2013 Jul 5;711(1-3):57-62. doi: 10.1016/j.ejphar.2013.04.025. Epub 2013 May 3. Review. PubMed PMID: 23648561.

11: Takagi H, Niwa M, Mizuno Y, Yamamoto H, Goto SN, Umemoto T. Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials. Heart Vessels. 2014 May;29(3):287-99. doi: 10.1007/s00380-013-0358-6. Epub 2013 May 5. Review. PubMed PMID: 23644555.

12: Aggarwal RK, Showkathali R. Rosuvastatin calcium in acute coronary syndromes. Expert Opin Pharmacother. 2013 Jun;14(9):1215-27. doi: 10.1517/14656566.2013.789860. Epub 2013 Apr 11. Review. PubMed PMID: 23574635.

13: DiNicolantonio JJ, Lavie CJ, Serebruany VL, O'Keefe JH. Statin wars: the heavyweight match--atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgrad Med. 2013 Jan;125(1):7-16. doi: 10.3810/pgm.2013.01.2620. Review. PubMed PMID: 23391667.

14: Zateĭshchikov DA. [Features of the use of rosuvastatin in clinical practice]. Kardiologiia. 2012;52(11):80-5. Review. Russian. PubMed PMID: 23237400.

15: Drapkina OM, Korneeva ON. [How to prolong life of patients at high cardiovascular risk. Features of rosuvastatin]. Kardiologiia. 2012;52(8):89-92. Review. Russian. PubMed PMID: 23098406.

16: Barrios V, Escobar C. Rosuvastatin and diabetes: when the evidences talk. Cardiovasc Hematol Agents Med Chem. 2013 Jun;11(2):115-24. Review. PubMed PMID: 23094943.

17: Gogolashvili NG. [Atorvastatin or rosuvastatin? Select from the perspective of evidence-based medicine]. Kardiologiia. 2012;52(7):84-92. Review. Russian. PubMed PMID: 22839720.

18: Nohara R. [COSMOS (coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects) trial]. Nihon Rinsho. 2011 Nov;69 Suppl 9:341-4. Review. Japanese. PubMed PMID: 22724226.

19: Nicholls SJ, Uno K, Kataoka Y. Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk. Expert Rev Cardiovasc Ther. 2011 Nov;9(11):1383-90. doi: 10.1586/erc.11.145. Review. PubMed PMID: 22059787.

20: Toth PP, Dayspring TD. Drug safety evaluation of rosuvastatin. Expert Opin Drug Saf. 2011 Nov;10(6):969-86. doi: 10.1517/14740338.2012.626764. Review. PubMed PMID: 21999163.